BACKGROUND:Administering inactivated influenza vaccine (IIV), 13-valent pneumococcal conjugate vaccine (PCV13), and diphtheria-tetanus-acellular pertussis (DTaP) vaccine together has been associated with increased risk for febrile seizure after vaccination. We assessed the effect of administering IIV at a separate visit from PCV13 and DTaP on postvaccination fever. METHODS:In 2017-2018, children aged 12 to 16 months were randomly assigned to receive study vaccines simultaneously or sequentially. They had 2 study visits 2 weeks apart; nonstudy vaccines were permitted at visit 1. The simultaneous group received PCV13, DTaP, and quadrivalent IIV (IIV4) at visit 1 and no vaccines at visit 2. The sequential group received PCV13 and DTaP at visit 1 and IIV4 at visit 2. Participants were monitored for fever (≥38°C) and antipyretic use during the 8 days after visits. RESULTS: There were 110 children randomly assigned to the simultaneous group and 111 children to the sequential group; 90% received≥1 nonstudy vaccine at visit 1. Similar proportions of children experienced fever on days 1 to 2 after visits 1 and 2 combined (simultaneous [8.1%] versus sequential [9.3%]; adjusted relative risk = 0.87 [95% confidence interval 0.36-2.10]). During days 1 to 2 after visit 1, more children in the simultaneous group received antipyretics (37.4% vs 22.4%; P = .020). CONCLUSIONS: In our study, delaying IIV4 administration by 2 weeks in children receiving DTaP and PCV13 did not reduce fever occurrence after vaccination. Reevaluating this strategy to prevent fever using an IIV4 with a different composition in a future influenza season may be considered.
RCT Entities:
BACKGROUND: Administering inactivated influenza vaccine (IIV), 13-valent pneumococcal conjugate vaccine (PCV13), and diphtheria-tetanus-acellular pertussis (DTaP) vaccine together has been associated with increased risk for febrile seizure after vaccination. We assessed the effect of administering IIV at a separate visit from PCV13 and DTaP on postvaccination fever. METHODS: In 2017-2018, children aged 12 to 16 months were randomly assigned to receive study vaccines simultaneously or sequentially. They had 2 study visits 2 weeks apart; nonstudy vaccines were permitted at visit 1. The simultaneous group received PCV13, DTaP, and quadrivalent IIV (IIV4) at visit 1 and no vaccines at visit 2. The sequential group received PCV13 and DTaP at visit 1 and IIV4 at visit 2. Participants were monitored for fever (≥38°C) and antipyretic use during the 8 days after visits. RESULTS: There were 110 children randomly assigned to the simultaneous group and 111 children to the sequential group; 90% received ≥1 nonstudy vaccine at visit 1. Similar proportions of children experienced fever on days 1 to 2 after visits 1 and 2 combined (simultaneous [8.1%] versus sequential [9.3%]; adjusted relative risk = 0.87 [95% confidence interval 0.36-2.10]). During days 1 to 2 after visit 1, more children in the simultaneous group received antipyretics (37.4% vs 22.4%; P = .020). CONCLUSIONS: In our study, delaying IIV4 administration by 2 weeks in children receiving DTaP and PCV13 did not reduce fever occurrence after vaccination. Reevaluating this strategy to prevent fever using an IIV4 with a different composition in a future influenza season may be considered.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jonathan Duffy; Eric Weintraub; Simon J Hambidge; Lisa A Jackson; Elyse O Kharbanda; Nicola P Klein; Grace M Lee; S Michael Marcy; Cynthia C Nakasato; Allison Naleway; Saad B Omer; Claudia Vellozzi; Frank DeStefano Journal: Pediatrics Date: 2016-06-06 Impact factor: 7.124
Authors: W E Barlow; R L Davis; J W Glasser; P H Rhodes; R S Thompson; J P Mullooly; S B Black; H R Shinefield; J I Ward; S M Marcy; F DeStefano; R T Chen; V Immanuel; J A Pearson; C M Vadheim; V Rebolledo; D Christakis; P J Benson; N Lewis Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Rongxia Li; Brock Stewart; Michael M McNeil; Jonathan Duffy; Jennifer Nelson; Alison Tse Kawai; Roger Baxter; Edward A Belongia; Eric Weintraub Journal: Pharmacoepidemiol Drug Saf Date: 2016-04-01 Impact factor: 2.890
Authors: Alexander I Klimov; Rebecca Garten; Colin Russell; Ian G Barr; Terry G Besselaar; Rod Daniels; Othmar G Engelhardt; Gary Grohmann; Shigeyuki Itamura; Anne Kelso; John McCauley; Takato Odagiri; Derek Smith; Masato Tashiro; Xiyan Xu; Richard Webby; Dayan Wang; Zhiping Ye; Shu Yuelong; Wenqing Zhang; Nancy Cox Journal: Vaccine Date: 2012-08-20 Impact factor: 3.641
Authors: Lisa A Grohskopf; Lenee H Blanton; Jill M Ferdinands; Jessie R Chung; Karen R Broder; H Keipp Talbot; Rebecca L Morgan; Alicia M Fry Journal: MMWR Recomm Rep Date: 2022-08-26